Some of these aberrations are not unique to IDH-mutant gliomas, such as increased choline peak near 3.2 ppm, which sums contributions from multiple choline-containing metabolites, including free choline, phosphorylcholine, and glycerophosphorylcholine. The gene discussed is IDH2; the disease is central nervous system cancer.